Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection

Outline

Abstract
Keywords

Frontiers of Medicine

PDF
collect

Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection

10.1007/s11684-021-0834-9

Cite this article

Abstract

Zika virus (ZIKV) is an emerging pathogen associated with neurological complications, such as Guillain–Barré syndrome in adults and microcephaly in fetuses and newborns. This mosquito-borne flavivirus causes important social and sanitary problems owing to its rapid dissemination. However, the development of antivirals against ZIKV is lagging. Although various strategies have been used to study anti-ZIKV agents, approved drugs or vaccines for the treatment (or prevention) of ZIKV infections are currently unavailable. Repurposing clinically approved drugs could be an effective approach to quickly respond to an emergency outbreak of ZIKV infections. The well-established safety profiles and optimal dosage of these clinically approved drugs could provide an economical, safe, and efficacious approach to address ZIKV infections. This review focuses on the recent research and development of agents against ZIKV infection by repurposing clinical drugs. Their characteristics, targets, and potential use in anti-ZIKV therapy are presented. This review provides an update and some successful strategies in the search for anti-ZIKV agents are given.

Keywords

Zika virus ; clinical drugs ; ZIKV inhibitors ; antivirals ; repurposing

Previous article in issue

article in issue Next

Read

Download

Outline

Figures(5)

标签(1)

其他(2)

Frontiers of Medicine

Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection

Abstract

Keywords

评论

Outline

Figures(5)

标签(1)

其他(2)

Frontiers of Medicine

Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection

Abstract

Keywords

评论

Related Research